Equities research analysts predict that Monopar Therapeutics Inc. (NASDAQ:MNPR) will report earnings of ($0.22) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Monopar Therapeutics’ earnings. Monopar Therapeutics reported earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year over year growth rate of 120%. The firm is expected to issue its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Monopar Therapeutics will report full-year earnings of ($1.25) per share for the current year, with EPS estimates ranging from ($1.37) to ($1.12). For the next year, analysts anticipate that the business will post earnings of ($1.53) per share, with EPS estimates ranging from ($1.54) to ($1.51). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Monopar Therapeutics.
Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02.
In other news, major shareholder Tactic Pharma Llc sold 125,000 shares of the company’s stock in a transaction dated Thursday, February 11th. The shares were sold at an average price of $14.64, for a total transaction of $1,830,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 48.40% of the stock is owned by insiders.
An institutional investor recently raised its position in Monopar Therapeutics stock. BlackRock Inc. increased its holdings in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 99.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,391 shares of the company’s stock after acquiring an additional 2,688 shares during the period. BlackRock Inc.’s holdings in Monopar Therapeutics were worth $33,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.66% of the company’s stock.
Shares of NASDAQ:MNPR opened at $5.15 on Friday. The company’s 50 day simple moving average is $6.59 and its 200 day simple moving average is $6.20. The stock has a market capitalization of $64.72 million and a price-to-earnings ratio of -8.05. Monopar Therapeutics has a 1 year low of $4.28 and a 1 year high of $17.01.
About Monopar Therapeutics
Monopar Therapeutics Inc, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers.
Featured Story: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.